lifestyle.sourcefed.com

Author: X4 Pharmaceuticals

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

April 29, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 1, 2026
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 17, 2026
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

March 4, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 2, 2026
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026

February 10, 2026
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2026